Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Top Cited Papers
Open Access
- 13 February 2003
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 348 (7), 601-608
- https://doi.org/10.1056/nejmoa020888
Abstract
Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of these antibodies in patients with Crohn's disease.Keywords
This publication has 17 references indexed in Scilit:
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.Inflammatory Bowel Diseases, 2001
- Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patientsThe American Journal of Gastroenterology, 2001
- Infliximab in Crohn's Disease: First Anniversary Clinical ExperienceThe American Journal of Gastroenterology, 2000
- Clinical Experience With Infliximab Therapy in 100 Patients With Crohn's DiseaseThe American Journal of Gastroenterology, 2000
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisThe New England Journal of Medicine, 2000
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Review article: safety of infliximab in clinical trialsAlimentary Pharmacology & Therapeutics, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseThe New England Journal of Medicine, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseThe New England Journal of Medicine, 1997